Table V.
Characteristics of the lyophilized NAd | Formulations
|
||||||
---|---|---|---|---|---|---|---|
F1a | F2b | F1 Combc | Paclitaxel as received | Cisplatin as received | |||
At flow rate of ~30 L/min | % EFe | 72±5 | 72±15 | 78±1 | 68±6 | 70±1 | |
% FPFf | <5.7 | 96±3 | 95±4 | 79±1 | 0.4±0.3 | 0.3±0.4 | |
<3.3 | 84±3 | 80±5 | 71±1 | 0 | 0 | ||
MMADg | 1.5±0.1 | 1.9±0.4 | 1.8±0.04 | 9.5±0.04 | 9.5±0.1 | ||
GSDh | 2.2±0.1 | 2.3±0.1 | 2.2±0.2 | 1.9±0.1 | 3.5±0.1 |
F1=0.1:0.02:0.01; Px:Lec:PVP K90
F2=0.1:0.02; Px:Lec
F1 Comb=3:2; PX:CP
NA: nanoparticle agglomerates
% EF: percent emitted fraction
FPF: fine particle fraction
MMAD: mass median aerodynamic diameter obtained from cascade impactor
GSD: geometric standard deviation